How does startup show work?

“Startup show” can mean a TV-style pitch program, a demo day (accelerator showcase), or a conference pitch stage (e.g., a medtech innovation theater). In all cases, the mechanics are similar: it’s a curated funnel designed to compress months of networking into a few weeks by standardizing how startups are discovered, compared, and introduced to investors, hospitals, and strategic partners.

In medtech, the show is rarely just about charisma. Judges and investors are quietly scoring you on regulatory pathway (510(k), De Novo, PMA), clinical evidence plan (often IRB-related), reimbursement (CPT codes, coverage, payment), and hospital procurement reality. Below is how the process typically works and how to use it to move your company forward.

1) The startup show is a funnel: application → selection → coaching → pitch → follow-ups

Most startup shows follow the same pipeline, even if the branding differs.

1. Application / nomination: You submit a deck and short form (problem, solution, traction, team, market, ask). Some shows accept nominations from VCs, accelerators, or hospital innovation offices.
2. Screening: Producers or program managers filter for fit (stage, category, geography) and “story.” In medtech, they also check for obvious red flags: unclear indication for use, unrealistic FDA plan, or no path to payment.
3. Selection: A smaller group is chosen. Selection is often about comparability (they want a mix of categories and stages) and credibility (can you survive questions on safety, evidence, and adoption?).
4. Coaching / prep: Many programs provide pitch coaching, narrative refinement, and sometimes mock Q&A. Treat this as free consulting: your goal is not a prettier deck; it’s a tighter business model.
5. The pitch event: You pitch (often 3–8 minutes) and answer Q&A. The audience may include investors, strategics, clinicians, and procurement-adjacent stakeholders.
6. Post-show conversion: The real value is the next 2–6 weeks: meetings, diligence requests, pilot discussions, and partnership intros.

Think of the pitch as the top of funnel (awareness). The win is converting that attention into qualified next steps: a second meeting, a site visit, a pilot LOI, or a diligence data room request.

2) What judges and investors are actually evaluating in medtech

On stage, you’re selling a vision. Off stage, you’re being evaluated like a risk-reduction project. In medtech, the biggest risks are clinical, regulatory, reimbursement, and adoption.

• Clinical problem clarity: Is the unmet need real, frequent, and costly? Can a clinician describe the pain in one sentence?
• Indication for use + target user: Who uses it, on whom, and in what setting (OR, ICU, outpatient, home)? If you can’t define this, your FDA and reimbursement plans will be shaky.
• Regulatory pathway realism: Do you credibly fit 510(k) (substantial equivalence), De Novo (novel moderate risk), or PMA (high risk)? You don’t need a final answer on day one, but you must show you’ve done the homework and have a plan to de-risk it.
• Evidence strategy: What data do you need for clearance/approval and for adoption? These can differ. Investors like to see a staged plan: bench testing → usability/human factors → feasibility clinical study → pivotal (if needed). IRB approval and study ops competence matter.
• Reimbursement logic: If payment depends on CPT codes, coverage decisions, or DRG economics, say so plainly. If you’re relying on “hospitals will pay because it’s better,” expect pushback. A credible plan might include existing CPT usage, a pathway to new code (varies), or a value story aligned to hospital cost centers.
• Hospital procurement reality: Who signs? Materials management? Value analysis committee? Department chair? Supply chain? If your sales cycle assumes one champion can buy, you’ll be challenged.
• Business model: Per-procedure, per-device, subscription, usage-based, or enterprise? In digital health, “per clinician per month” is common, but you must show why it survives procurement and compliance review.
• Traction that matches stage: For early medtech, traction can be KOL letters, pilot sites, IRB-ready protocol, pre-sub meetings, or manufacturing feasibility—not necessarily revenue.
• Team completeness: Clinical credibility is great; investors also look for regulatory, quality (QMS), reimbursement, and go-to-market competence.

3) The pitch format: what to include (and what to avoid)

Most startup shows reward clarity and risk reduction. A medtech pitch that wins meetings usually answers these questions quickly:

A simple 10-slide structure that works

1. Patient + clinical workflow problem (one sentence + who/where)
2. Why now (technology shift, guideline change, policy, or workflow pressure)
3. Solution (what it is, how it’s used, what it replaces)
4. Clinical benefit (outcomes) and economic benefit (cost/time/complications)
5. Evidence to date (bench, preclinical, retrospective, feasibility—be precise)
6. Regulatory plan (510(k)/De Novo/PMA hypothesis + milestones; avoid overpromising timelines)
7. Reimbursement / payment plan (existing codes/coverage assumptions; who pays)
8. Go-to-market (buyer, sales motion, pilots → contracts; procurement steps)
9. Competition + differentiation (including standard of care)
10. Ask (capital, pilots, strategic partners) + what milestones it funds

Common medtech pitch mistakes on “startup shows”

• Skipping the indication for use and speaking only in broad “AI improves care” terms.
• Confusing FDA clearance with adoption: clearance doesn’t guarantee hospitals will buy; you still need value analysis and reimbursement logic.
• Overstating regulatory certainty: if you haven’t talked to FDA (or a regulatory expert), present it as a plan with assumptions.
• Ignoring integration and compliance in digital health (EHR integration, security review, clinical governance).
• Vague traction: “We have interest” is weaker than “3 LOIs for pilots pending IRB” (if true).

4) What happens after the show: diligence, pilots, and term sheets

If the show works, you’ll get inbound requests. Your job is to turn that into a structured process rather than a chaotic inbox.

Typical post-show requests

• Data room (a shared folder of key documents): deck, cap table, IP status, regulatory plan, study summaries, QMS status, risk analysis, and any customer/pilot documents.
• Clinical validation details: endpoints, study design, inclusion/exclusion, comparator, and how you’ll handle IRB and site contracting.
• Regulatory and quality: design controls, intended use, risk management, and how you’ll manufacture/scale under a QMS.
• Reimbursement and pricing: how pricing ties to savings or revenue; how you avoid “nice-to-have” status in value analysis.
• Customer discovery evidence: notes from clinician interviews, procurement conversations, and workflow mapping.

Funding may happen, but many medtech “wins” are pilot pathways: a hospital agrees to evaluate, a strategic partner offers a co-development conversation, or an accelerator invites you in. Treat pilots like mini-sales: define success metrics, timeline, data ownership, and what converts to a paid contract.

5) How to maximize your odds on a medtech startup show

Because stage time is short, your advantage comes from preparation and clarity.

• Pre-wire the room: before the event, identify 10–20 target attendees (investors, strategics, hospital innovation leads) and request short meetings. The pitch then becomes a credibility amplifier, not your first touch.
• Have one “regulatory slide” and one “payment slide”: even if early, show you understand the pathway and the unknowns.
• Translate clinical value into hospital language: fewer complications, shorter length of stay, reduced readmissions, OR time saved, staffing efficiency—choose the metric that matches your buyer.
• Make the ask specific: “We’re raising X” is less useful than “We’re raising to fund these milestones: design freeze, verification/validation, and a feasibility study” (amounts and timelines vary, but the milestone logic should be crisp).
• Prepare for the three hardest questions: (1) Why will hospitals pay? (2) What’s the FDA path and key risks? (3) What evidence will change behavior?

What to do next

1. Build a one-page “medtech diligence brief”: indication for use, target user, FDA pathway hypothesis (510(k)/De Novo/PMA), evidence plan, reimbursement assumptions, and procurement path.
2. Set up a lightweight data room with your deck, IP summary, study summaries, and a clear milestones roadmap so you can respond within 24 hours after the show.
3. Run a competitor and standard-of-care map so your differentiation is defensible on stage and in follow-ups.
4. Practice Q&A with a clinician and a non-clinical buyer (procurement/value analysis mindset) to stress-test adoption and payment.
5. Pressure-test your pitch using StartupLaby tools before you apply or go on stage.

Related StartupLaby tools: /roast, /Competitor_study, /launchpad, /Simulator